Literature DB >> 12935982

The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes.

Robin Parisotto1, Michael J Ashenden, Christopher J Gore, Ken Sharpe, Will Hopkins, Allan G Hahn.   

Abstract

BACKGROUND AND OBJECTIVES: Algorithms that combine scores from multiple blood parameters are demonstrably effective in highlighting recombinant human erythropoietin (rHuEPO) administration, and have been used to deter rHuEPO use by athletes. These models are sensitive to atypical levels of blood parameters encountered during altered states of red cell production. Because hematologic abnormalities can also result in unusual blood profiles, the aim of this study was to document the incidence and magnitude of such abnormalities in an elite athlete population. DESIGN AND METHODS: We screened blood samples obtained from 413 female and 739 male elite athletes from 12 countries for known hematologic abnormalities, and compared the algorithm scores for these athletes with those of their healthy counterparts. We also established the magnitude of blood parameters required for model scores to exceed cut-offs associated with rHuEPO use.
RESULTS: We found that 0.7% of male and 2.4% of female athletes were iron deficient either with our without anemia. An additional 1.4% of males and 1.0% of females had hemoglobinopathies. On average these athletes' model scores were at or below the score of their healthy counterparts. The greatest influence on our models was hemoglobin concentration. Values of other parameters must exceed normal ranges by a substantial margin in order for model scores to approach levels associated with rHuEPO use. INTERPRETATION AND
CONCLUSIONS: The hematologic disorders we encountered in elite athletes were not associated with model scores that exceeded the nominal cut-offs that we have previously recommended to delineate rHuEPO use. We did not find any abnormalities among elite endurance athletes that were associated with high model scores.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12935982

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  5 in total

Review 1.  Oxygen delivery enhancers: past, present, and future.

Authors:  P Borrione; A Mastrone; R A Salvo; A Spaccamiglio; L Grasso; A Angeli
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

Review 2.  Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era.

Authors:  Evanthia Diamanti-Kandarakis; Panagiotis A Konstantinopoulos; Joanna Papailiou; Stylianos A Kandarakis; Anastasios Andreopoulos; Gerasimos P Sykiotis
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

3.  Effect of intermittent hypoxia on hematological parameters after recombinant human erythropoietin administration.

Authors:  F Sanchis-Gomar; V E Martinez-Bello; E Domenech; A L Nascimento; F V Pallardo; Mari Carmen Gomez-Cabrera; J Vina
Journal:  Eur J Appl Physiol       Date:  2009-08-08       Impact factor: 3.078

4.  Comprehensive Sports Medicine Treatment of an Athlete Who Runs Cross-Country and is Iron Deficient.

Authors:  Jason Brumitt; Linda McIntosh; Richard Rutt
Journal:  N Am J Sports Phys Ther       Date:  2009-02

5.  Erythropoietin use and abuse.

Authors:  M Joseph John; Vineeth Jaison; Kunal Jain; Naveen Kakkar; Jubbin J Jacob
Journal:  Indian J Endocrinol Metab       Date:  2012-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.